Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder
NCT ID: NCT02602886
Last Updated: 2016-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
48 participants
INTERVENTIONAL
2016-11-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure and Response Prevention Therapy
Exposure and Response Prevention Therapy
The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure and Response Prevention Therapy
The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Medically healthy
* Outpatient men and women age 18 years and older;
* Meets DSM-IV criteria for a diagnosis of OCD as determined by the MINI. OCD is the primary psychiatric diagnosis (i.e., it is defined by the patient as the most important source of current distress);
* Able to communicate meaningfully with the investigators and competent to provide written informed consent. IQ estimate \> 85 standard score.
Exclusion Criteria
* Presence of any clinical features requiring a higher level of care (inpatient or partial hospital treatment);
* Current or past DSM-IV bipolar disorder (Current or past unipolar depression is not an exclusion criterion. We will allow comorbid depression, to ensure that we are treating a representative OCD sample. Depression is the most common complication in OCD, and about one third of the OCD clinical samples are depressed.)
* Schizophrenia, schizoaffective disorder, or any other current or lifetime DSM-IV psychotic disorder;
* Current or recent (within 3 months of study entry) DSM-V alcohol or drug dependence or abuse (other than nicotine), or a positive urine drug screen for any illicit substances of abuse;
* Estimated IQ \<85 on the WASI, mental retardation, dementia, brain damage, or other cognitive impairment that would interfere with the capacity to participate in the study and complete self-report measures;
* Any medical conditions that might contraindicate use of the study treatments, as determined by medical physical and laboratory tests by the study physicians;
* Presence of any significant and/or unstable medical illness which might lead to hospitalization during the study duration; subjects with a stable medical condition may participate with the agreement of the subject's physician and the study physician who performs the study physical exam;
* Concurrent psychotherapy of any type (e.g., CBT/ERP, supportive, psychodynamic) and duration;
* History of adequately-delivered exposure-based cognitive-behavioral therapy (i.e., 10 or more sessions of specific and regular exposure and/or response prevention assignments; as needed and with patients' written permission we will confer with prior treatment providers).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Hongkou Mental Health Center
UNKNOWN
West China Hospital
OTHER
Suzhou Guangji Hospital
UNKNOWN
First Affiliated Hospital of Xinjiang Medical University
OTHER
The SHSMU-ION Research Center for Brain Disorders
UNKNOWN
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bomin Sun
Director of Functional Neurosurgery Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bomin Sun, MD, PhD
Role: STUDY_DIRECTOR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China
West China Hospital
Chengdu, Sichuan, China
Shanghai Hongkou Mental Health Center
Shanghai Shi, , China
Suzhou Guangji Hospital
Suzhou, , China
The First Hospital affiliated to XinJiang Medical University
Ürümqi, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Haiyan Jin, MD,PhD
Role: primary
Chencheng Zhang, MD,PhD
Role: backup
Bin Li, MD,PhD
Role: primary
Fang Fang, MD
Role: primary
Feng Zhu, MD
Role: primary
Xiao Luo, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCD#020
Identifier Type: -
Identifier Source: org_study_id